Description
FHD-286 is a BRG1/BRM ATPase inhibitor, which is associated with tumor development and progression.
FHD-286
Product ID F130280
Cas No. 2671128-05-3
Purity ≥98%
| Product Unit Size | Cost | Quantity | Stock |
|---|
Product Info
| Cas No. | 2671128-05-3 |
|---|---|
| Purity | ≥98% |
| Formula | C24H30N6O6S2 |
| Formula Wt. | 562.66 |
| IUPAC Name | N-[(2S)-1-[[4-[6-[(2S,6R)-2,6-dimethylmorpholin-4-yl]pyridin-2-yl]-1,3-thiazol-2-yl]amino]-3-methoxy-1-oxopropan-2-yl]-1-methylsulfonylpyrrole-3-carboxamide |
| Synonym | FHD286 |
| Appearance | Off white solid |
Shipping and Storage
| Store Temp | -20°C |
|---|---|
| Ship Temp | Ambient |
Downloads
| Info Sheet |
|---|
References
Rago F, Rodrigues L, Bonney M, et al. Exquisite sensitivity to dual BRG1/BRM ATPase inhibitors reveals broad SWI/SNF dependencies in acute myeloid leukemia. Mol Cancer Res. 2022 Mar 1;20(3):361-372. PMID: 34799403
Matsubara D, Kishaba Y, Ishikawa S, et al. Lung cancer with loss of BRG1/BRM, shows epithelial mesenchymal transition phenotype and distinct histologic and genetic features. Cancer Sci. 2013 Feb;104(2):266-273. PMID: 23163725
Sun A, Tawfik O, Gayed B, et al. Aberrant expression of SWI/SNF catalytic subunits BRG1/BRM is associated with tumor development and increased invasiveness in prostate cancers. Prostate. 2007 Feb 1;67(2):203-213. PMID: 17075831